By Marie Rosenthal, MS
Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec, Novartis).
After nearly two years of generic competition, the price for a month of treatment dropped by only 10%, according to authors from Vanderbilt University School of Medicine (VUSM) and the University of North Carolina at Chapel Hill (Health Aff 2018 May 7. [Epub ahead of print]).
“Most estimates of price reductions due to generic entry assume prices will drop by as much as